Adverum Biotechnologies, a clinical-stage biotechnology company, is focused on developing groundbreaking gene therapy product candidates to treat ocular and rare diseases. The company's main product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy designed to be used for the treatment of chronic retinal diseases, which include wet age-related macular degeneration and diabetic macular edema. Another noteworthy product in their pipeline is ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy candidate for the treatment of blue cone monochromacy that uses a single intravitreal injection. Adverum has collaborated with a number of esteemed institutions and companies, including the University of California, GenSight Biologics, Lexeo Therapeutics, and Virovek, to diligently advance their gene therapy platform. Previously known as Avalanche Biotechnologies, Adverum rebranded in May 2016. The company was founded in 2006 and is headquartered in Redwood City, California.